Investing in Tomorrow's Health
NCL Technology Ventures invests transformational equity capital in entrepreneurs who have truly innovative technologies.
Our Investment Strategy
We invest in Seed and Series A rounds where we can deploy our expertise and capital to help our companies achieve an early inflection point in valuation. We consciously choose investments that create an impact on the lives of patients as well as financial return for our investors.
Our Value Add:
We provide a package of human and capital resources over the life of our investments including:
- – Strong scientific knowledge and frontline healthcare experience
- – Developmental and leadership building experience
- – A carefully built local and global network of healthcare specialists
- – An overriding ambition to succeed in bringing new innovation in healthcare to benefit global recipients
“We are pleased with the performance of Fund 1 and have therefore decided to back Fund 2 as a cornerstone investor.”
– Health Technology Fund II LP
NCLs Health Technology Fund II
NCL has recently launched it Health Technology Fund II. The fund has been designed to take positions in pioneering new technologies that can create significant patient impact and produce upper quartile investment returns.
The fund has launched in partnership with several leading UK institutions including Kings College, NHS and our delivery partner Catalent Inc (NYSE: CLT). Documentation can be provided to professional investors only upon request.
Whether a potential investor or an entrepreneur we invite you to discuss your goals and ambitions with us.
Our team spans three generations and is vastly experienced in venture investment, fund structuring, entrepreneurship and business management and is supported by an expert Scientific Advisory Board.
Porfolio company TC BioPharm has had their T-cell therapy approved for trials in Scotland for Covid-19 that would boost patients’ immune systems before their need for … Continued
NCL is delighted to welcome Curesponse to our portfolio, a breakthrough cancer precision medicine company. Their platform, cResponse, accurately and quickly predicts a patient’s … Continued
Fantastic to see the Telegraph and the Daily Mail covering the work of TC BioPharm, one of our portfolio companies. Talks with government are … Continued